In association with
CONTENTS
Special Issue | October 2018
How will the rise of personalised medicine change manufacturing for drugmakers?
The high price behind one of the industry’s most advanced therapies
How can AI help doctors rapidly identify optimal personalised drug combinations?
Is the microbiome as important for precision medicine as genetics?
Has a summer of manufacturing disasters for Chinese pharma impacted trust?
ContraFect’s Staph infection drug may succeed in trials, but caveats remain
Why are novel therapies for glioblastoma patients not gaining approvals?
CAR-T has been approved in Europe, but with NICE divided, what happens next?
Life sciences firms need to adapt how they approach data management
The industry is undergoing dramatic change as new tech brings disruption